# Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT06454409** · PHASE1 · SUSPENDED · sponsor: **City of Hope Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- Myelodysplastic Syndrome/Acute Myeloid Leukemia
- Recurrent Acute Myeloid Leukemia
- Recurrent Myelodysplastic Syndrome
- Refractory Acute Myeloid Leukemia
- Refractory Myelodysplastic Syndrome

## Interventions

- **DRUG:** Azacitidine
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **DRUG:** Regorafenib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT06454409
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-05-21
- **Primary completion:** 2030-09-06
- **Final completion:** 2030-09-06
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** resources
- **Last updated:** 2025-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06454409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06454409, "Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06454409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*